Securities Class Action Filed Against Unicycive Over OLC NDA Statements
UNCY sits 23% above its 52-week low of $3.75.
Summary
Unicycive disclosed a securities class action lawsuit filed September 3, 2026, alleging misleading statements about its OLC NDA. The company says the claims are meritless and it will defend vigorously.
Key Events · Legal and Risk Events · UNCY
-
Securities Class Action Filed
A class action was filed September 3, 2026 in the Northern District of California against Unicycive and certain officers, alleging violations of federal securities laws related to public statements about the OLC NDA for hyperphosphatemia in CKD patients on dialysis.
-
Company Response
Unicycive states it believes the claims are meritless and intends to vigorously defend the lawsuit.
-
Regulatory Backdrop
The lawsuit follows two prior Complete Response Letters for OLC disclosed in the Q2 2026 10-Q, adding litigation risk to an already challenged regulatory path.
-
Financial Context
Unicycive reported $13.8M operating cash burn in Q2 2026, offset by $34.0M in ATM proceeds, with $61.4M cash providing a 12-month runway.
Analysis · UNCY · Life Sciences
A securities class action was filed against Unicycive and certain officers on September 3, 2026, alleging federal securities law violations tied to public statements about the oxylanthanum carbonate phosphate binder NDA. This is the first public disclosure of the suit. The company calls the claims meritless and plans to defend vigorously. The lawsuit lands against a backdrop of two prior CRLs for OLC and a $13.8M quarterly cash burn, so litigation risk now compounds an already difficult regulatory path.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, UNCY was trading at $4.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $129.2M. The 52-week trading range was $3.75 to $8.74. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.